Sat.Nov 19, 2022 - Fri.Nov 25, 2022

article thumbnail

Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line

Fierce Pharma

Sporting a $3.5M price tag, CSL and uniQure's hemophilia B gene therapy crosses FDA finish line. zbecker. Wed, 11/23/2022 - 10:10.

FDA 301
article thumbnail

AI will continue to attract investment in near future in the healthcare industry

Pharmaceutical Technology

Artificial intelligence (AI) was seen as one of the top current investment priorities and was thought to continue to attract investment in the healthcare sector in the upcoming two years, according to GlobalData's latest report ‘Digital Transformation and Emerging Technology in the Healthcare Industry - 2022 Edition’. In this survey-based report tracker, digital media was prioritised as a top current investment target, with 53% of surveyed respondents confirming that their companies are currentl

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

First-in-human gene therapy trial for major cardiac syndrome

European Pharmaceutical Review

The first-in-human gene therapy trial for heart failure patients with preserved ejection fraction (HFpEF) has been approved by the US Food & Drug Administration (FDA). SRD-001, the adenovirus associated virus (AAV)-based gene therapy is delivered to cardiac ventricular muscle cells via an intracoronary infusion system (produced by Sardocor, a clinical-stage gene therapy subsidiary of Medera), to increase the protein expression and functional activity of sarcoplasmic reticulum calcium ATPase

article thumbnail

Beware of a False Sense of Cybersecurity

MedCity News

Based on some independent research that my company commissioned with more than 200 companies, we came to several conclusions that are highlighted in the article. Broadly, however, it signals the false sense of (cyber)security that many companies are currently harboring.

Patients 138
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Senator aims to cut biosimilar 'red tape' with proposal to eliminate interchangeable status

Fierce Pharma

Senator aims to cut biosimilar 'red tape' with proposal to eliminate interchangeable status. kdunleavy. Wed, 11/23/2022 - 07:18.

291
291
article thumbnail

FDA starts speedy review of Takeda’s dengue vaccine

pharmaphorum

The US regulator has started a priority, six-month review of Takeda’s dengue fever vaccine TAK-003 – tipped as a potential blockbuster product – making a decision likely in the first half of 2023. The Japanese pharma said it has filed for approval of TAK-003 with the FDA for the prevention of dengue disease caused by any dengue virus serotype in individuals aged four through 60.

FDA 122

More Trending

article thumbnail

The Future of Digital Health and Healthcare IT in a Post-Covid World

MedCity News

Implementing and pursuing innovation in digital health and healthcare IT should be a priority for all U.S. healthcare providers and payers — especially as the lessons and response to the Covid-19 pandemic become permanently part of our everyday lives.

article thumbnail

On a roll, Takeda's dengue vaccine shifts into FDA's fast review lane

Fierce Pharma

On a roll, Takeda's dengue vaccine shifts into FDA's fast review lane. kdunleavy. Wed, 11/23/2022 - 09:35.

FDA 293
article thumbnail

Taking the right forecasting approach for rare diseases

pharmaphorum

There are approximately 7,000 different types of rare disease and researchers estimate that there are more than 300 million people worldwide living with such a condition, according to the National Institutes of Health (NIH). However, only 5% of rare diseases are estimated to have at least one approved treatment, known as “orphan” therapies. A rare disease is any disease that affects a small percentage of the population.

Marketing 119
article thumbnail

Using UHPLC-MS/MS for trace detection of ?-lactam antibiotics

European Pharmaceutical Review

A paper, published in Molecules , has developed validated the use of ultra-performance liquid chromatography with triple quadrupole mass spectrometry, or UHPLC-MS/MS, for identification and detection of the ?-lactams cephapirin and ceftiofur in cleaning solutions of the production reactors. Trace detection of ?-lactam antibiotics in cleaning rinse solutions and manufacturing aids in pharmaceutical facilities is crucial and regulated.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Why 1 VC is Fed Up with the Concept of Digital Health Unicorns

MedCity News

There are currently 97 global digital health companies that are considered unicorns. But getting caught up with the idea of digital health unicorns isn’t very sustainable, according to Emilly Melton, managing partner at Threshold Ventures. Instead of focusing too much on their valuations, she recommended that startups simply focus on getting the capital they need in order to reach the next stage of inflection.

article thumbnail

J&J's nasal spray Spravato bests former AZ drug Seroquel XR in treatment-resistant depression trial

Fierce Pharma

J&J's nasal spray Spravato bests former AZ drug Seroquel XR in treatment-resistant depression trial. fkansteiner. Wed, 11/23/2022 - 09:26.

262
262
article thumbnail

Provention prices type 1 diabetes drug Tzield at $194,000

pharmaphorum

Provention Bio has priced its new type 1 diabetes (T1D) prevention therapy Tzield at $13,850 per vial – equivalent to almost $194,000 for its 14-day course – a higher level than had been predicted by industry observers. The company argues that the cost is justified as Tzield (teplizumab) is the first drug that can delay the onset of type 1 diabetes, fending off the time when they become highly reliant on insulins and at risk of the serious complications that can accompany advanced T1D.

Insurance 115
article thumbnail

CAR-T therapy aids lupus remission

European Pharmaceutical Review

Patients with refractory systemic lupus erythematosus (SLE) were able to go into remission within three months of one small dose of a personalised anti-CD19 CAR T-cell immunotherapy in a clinical study. The German study showed all five young adult patients with systemic lupus erythematosus went into remission, enabling them to stop taking their lupus medications within three months of just one small dose of the CAR T therapy , as it essentially removed their existing B cells.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Unpaid Caregiving: A Growing Healthcare Burden Requiring Societal Intervention

MedCity News

November is National Family Caregivers Month in the US, an opportunity to honor those who have taken on this critical role of caring for loved ones, while raising awareness of the challenges they face daily and what needs to be done to drive tangible changes.

article thumbnail

ASH: AbbVie, J&J's Imbruvica under serious threat as BeiGene's Brukinsa delivers head-to-head trial win

Fierce Pharma

ASH: AbbVie, J&J's Imbruvica under serious threat as BeiGene's Brukinsa delivers head-to-head trial win. aliu. Mon, 11/21/2022 - 16:29.

252
252
article thumbnail

Ozempic compensating for Wegovy’s supply shortage due to high demand

Pharmaceutical Technology

In recent months, Wegovy (semaglutide), indicated for obesity, has been subjected to widespread supply shortages due to high demand, in addition to manufacturer production problems, with Novo Nordisk intending to relaunch Wegovy by the end of 2022. In the meantime, however, Novo Nordisk’s Ozempic, another version of semaglutide indicated particularly for patients with type 2 diabetes, has picked up the slack by being used off-label for obesity patients.

Marketing 111
article thumbnail

Clinical trials authorised for 3D-printed ulcerative colitis drug

European Pharmaceutical Review

Triastek, Inc. a China-based pharma company has announced it has received clearance for its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to initiate clinical studies of T21, a 3D-printed medicine that can target specific segments in the colon to more safely deliver oral ulcerative colitis (UC) drugs. T21 is Triastek’s third FDA IND clearance for a 3D-printed medicine.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

CSL’s Gene Therapy Approval Marks First for Hemophilia B and New High in Pricing

MedCity News

CSL Behring’s hemophilia B gene therapy, Hemgenix, carries a $3.5 million list price. But the company contends that by reducing economic burdens associated with bleeding and prophylactic infusions, the one-time treatment will save money over time.

FDA 113
article thumbnail

'Monopoly' allowed Bristol Myers and generics makers to 'steal' from Revlimid purchasers, lawsuit says

Fierce Pharma

'Monopoly' allowed Bristol Myers and generics makers to 'steal' from Revlimid purchasers, lawsuit says. kdunleavy. Tue, 11/22/2022 - 11:13.

241
241
article thumbnail

NICE questions value and efficacy of five Covid-19 drugs with rejection

Pharmaceutical Technology

The UK's National Institute for Health and Care Excellence (NICE) has published a draft guidance that does not recommend the use of five major Covid-19 therapies. This news came as many organisations and patient advocacy groups have been campaigning for the adoption of some of the rejected drugs for several months, amidst concerns about access to medicines in the UK.

Medicine 111
article thumbnail

Can holograms help in the frontline fight against pharmaceutical counterfeiting?

European Pharmaceutical Review

The European Union Intellectual Property Office/ Europol joint report confirms that counterfeit pharmaceuticals continue to be a big problem across the European Union zone and a substantial threat for most, if not all, member states. Indeed, a 2020 operation coordinated by Europol across 27 countries led to the seizure of more than 25 million units of counterfeit anticancer drugs and erectile dysfunction medicines among other fake drugs worth nearly €73 million.

article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Physicians, Heal Thy Billing Systems

MedCity News

Practices don’t need to lose out on uncollected payments from insurers. Here are steps you can take to better manage coding, tracking, communications and rise above byzantine insurance practices.

article thumbnail

Shionogi's COVID-19 antiviral nabs Japanese approval to rival drugs from Pfizer, Merck

Fierce Pharma

Shionogi's COVID-19 antiviral nabs Japanese approval to rival drugs from Pfizer, Merck. fkansteiner. Tue, 11/22/2022 - 10:07.

261
261
article thumbnail

Umoja and IASO partner to develop therapies for haematological malignancies

Pharmaceutical Technology

Umoja Biopharma has signed a research agreement with IASO Biotherapeutics (IASO Bio) to develop off-the-shelf therapies for haematological malignancies. Under the alliance, the companies will assess the induced cytotoxic innate lymphocytes (iCIL) platform of Umoja with chimeric antigen receptors (CARs) of IASO to develop the next generation of widely accessible, easily available cell therapies.

Biopharma 110
article thumbnail

EMA launches quality control group to aid medicine innovation

European Pharmaceutical Review

The European Medicines Agency (EMA) has established the Quality Innovation Expert Group (QIG) to aid innovative approaches for the development, manufacture and quality control (QC) of medicines, including new technologies, digitalisation, novel materials and novel devices for patients in the European Union (EU). The QIG, set up in September 2022, is composed of eight members with backgrounds in chemical, biological quality assessment and Good Manufacturing Practice (GMP) inspections, who report

Medicine 111
article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

Why You Need an ADA Compliant Healthcare Website—and How to Get One

Healthcare Success

Just like your brick-and-mortar business has to be ADA compliant, your healthcare website must also be accessible to people with disabilities. The problem? The ADA doesn’t offer clear regulations for a compliant website. The bigger problem? ADA accessibility lawsuits are on the rise. If your website isn’t accessible to people with disabilities, you could risk lawsuits, financial liabilities, and damage to your brand reputation.

article thumbnail

Teva, AbbVie's Allergan lock in $6.6B deal to settle thousands of US opioid lawsuits

Fierce Pharma

Teva, AbbVie's Allergan lock in $6.6B deal to settle thousands of US opioid lawsuits. fkansteiner. Wed, 11/23/2022 - 08:05.

253
253
article thumbnail

When It Comes to Dental Care, Convenience Isn’t a Luxury

MedCity News

For far too long, dentists have focused on drilling and billing rather than optimizing the patient experience — and that’s driving many of our patients away, with terrible results for their dental health.

Patients 116
article thumbnail

Therapeutic-first for cold agglutinin disease haemolytic anaemia

European Pharmaceutical Review

The European Commission (EC) has granted marketing authorisation for Enjaymo ® ( sutimlimab ), as the only approved treatment of haemolytic anaemia in adults with cold agglutinin disease (CAD). Enjaymo ® , Sanofi’s first-in-class humanised monoclonal antibody (mAb) is designed to inhibit the classical complement pathway specific serine protease, C1s, to prevent the abnormal destruction of healthy red blood cells.

Safety 111
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time